特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の急性反復性発作(ARS)の世界市場:市場規模、市場シェア、動向分析 - 製品(USL-261、NRL-1、AZ-002、ジアゼパムジェル)、国別(米国、英国、カナダ、ドイツ)別 2018年~2025年

Acute Repetitive Seizures Market Size, Share & Trends Analysis Report By Product (USL-261, NRL-1, AZ-002, Diastat Rectal Gel), By Region (U.S., U.K., Canada, Germany), And Segment Forecasts, 2018 - 2025

発行 Grand View Research, Inc. 商品コード 748458
出版日 ページ情報 英文 87 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=107.84円で換算しております。
世界の急性反復性発作(ARS)の世界市場:市場規模、市場シェア、動向分析 - 製品(USL-261、NRL-1、AZ-002、ジアゼパムジェル)、国別(米国、英国、カナダ、ドイツ)別 2018年~2025年 Acute Repetitive Seizures Market Size, Share & Trends Analysis Report By Product (USL-261, NRL-1, AZ-002, Diastat Rectal Gel), By Region (U.S., U.K., Canada, Germany), And Segment Forecasts, 2018 - 2025
出版日: 2018年11月12日 ページ情報: 英文 87 Pages
概要

世界の急性反復性発作(ARS)市場は、2018年から2025年にかけて47.8%のCAGRで推移し、2025年までに319億米ドル規模の市場に成長することが予測されています。てんかんの認知度向上を図る取り組みの増加によって当市場の成長が促進されています。

当レポートでは、世界の急性反復性発作(ARS)市場を調査し、市場の概要、製品・国別の市場規模の推移と予測、市場動向、市場の成長要因および阻害要因の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 調査方法と範囲

  • 調査方法
  • 調査範囲と前提条件
  • 情報源リスト

第2章 エグゼクティブサマリー

第3章 市場変数、動向、範囲

  • 市場区分
  • 市場力学
  • 成長要因の分析
  • 阻害要因の分析
  • 浸透度のマッピング
  • 医療提供者における投与経路の認識
  • 副作用として鎮静作用がでないことの重要性
  • 市場機会の分析

第4章 急性反復性発作(ARS)市場:製品別

  • 市場動向の分析:製品別
  • USL-261
  • NRL-1
  • AZ-002
  • ジアゼパムジェル
  • その他

第5章 急性反復性発作(ARS)市場:地域別

  • 市場シェアの分析
  • 北米(米国、カナダ)
  • 欧州(ドイツ、英国)
  • その他の地域

第6章 競合情勢

  • 戦略の枠組み
  • 企業プロファイル
    • UCB S.A. Belgium
    • Neurelis
    • Valeant Pharmaceuticals North America LLC
    • Alexza Pharmaceuticals
    • VERITON PHARMA
図表

List of Tables

  • Table 1 Acute Repetitive Seizures Pipeline, 2018
  • Table 2 Country share estimation
  • Table 3 North America acute repetitive seizures market, by product, 2013 - 2025 (USD Million)
  • Table 4 U.S. acute repetitive seizures market, by product, 2013 - 2025 (USD Million)
  • Table 5 Canada acute repetitive seizures market, by product, 2013 - 2025 (USD Million)
  • Table 6 Europe acute repetitive seizures market, by product, 2013 - 2025 (USD Million)
  • Table 7 Germany acute repetitive seizures market, by product, 2013 - 2025 (USD Million)
  • Table 8 U.K. acute repetitive seizures market, by product, 2013 - 2025 (USD Million)
  • Table 9 Rest of World acute repetitive seizures market, by product, 2013 - 2025 (USD Million)

List of Figures

  • Fig. 1 Market summary
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 QFD modelling for market share assessment
  • Fig. 6 Market trends & outlook
  • Fig. 7 Market segmentation & scope
  • Fig. 8 Global acute repetitive seizures market, 2013 - 2025 (USD Million)
  • Fig. 9 Market driver relevance analysis (Current & future impact)
  • Fig. 10 Market restrain relevance analysis (Current & future impact)
  • Fig. 11 Penetration & growth prospect mapping
  • Fig. 12 SWOT Analysis, By Factor (political & legal, economic and technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Acute repetitive seizures market product outlook key takeaways
  • Fig. 15 Acute repetitive seizures market: Product movement analysis
  • Fig. 16 Global USL-261 market, 2013 - 2025 (USD Million)
  • Fig. 17 Global Neurelis-1 market, 2013 - 2025 (usd million)
  • Fig. 18 Global AZ-002 market, 2013 - 2025 (USD Million)
  • Fig. 19 Global diastat rectal gel market, 2013 - 2025 (USD Million)
  • Fig. 20 Others market, 2013 - 2025 (USD Million)
  • Fig. 21 Regional market place: Key takeaways
  • Fig. 22 Acute repetitive seizures market: Regional movement analysis
  • Fig. 23 North America acute repetitive seizures market, 2013 - 2025 (USD Million)
  • Fig. 24 U.S. acute repetitive seizures market, 2013 - 2025 (USD Million)
  • Fig. 25 Canada acute repetitive seizures market, 2013 - 2025 (USD Million)
  • Fig. 26 Europe acute repetitive seizures market, 2013 - 2025 (USD Million)
  • Fig. 27 Germany acute repetitive seizures market, 2013- 2025 (USD Million)
  • Fig. 28 U.K. acute repetitive seizures market, 2013 - 2025 (USD Million)
  • Fig. 29 Rest of World acute repetitive seizures market, 2013 - 2025 (USD Million)
  • Fig. 30 Strategy framework
目次
Product Code: GVR-2-68038-489-5

The global acute repetitive seizures market size is expected to reach USD 3.19 billion by 2025, according to a new report by Grand View Research, Inc. The report also states that the market will expand at a strong CAGR of 47.8% during the forecast period. Rise in the number of initiatives to increase the awareness about epilepsy is the major factor driving the market.

The market is currently led by generic drugs which mainly include oral benzodiazepines (diazepam and lorazepam). Rectal diazepam is the only approved drug for use in U.S. and buccal midazolam in European Union. Other drugs, such as diazepam (oral and intramuscular), midazolam (buccal, intranasal, intramuscular), lorazepam (oral, intranasal, sublingual), and progesterone are majorly used off label. The market is expected to be consolidated with few major companies and high market share.

Furthermore, in an attempt to curb healthcare expenditure, governments are making continuous efforts to reduce hospital stays and on-site treatment costs via outpatient care models, such as clinic and home healthcare. Emerging economies like India and China, are increasingly implementing such healthcare reform, which is expected to propel the growth of acute repetitive seizures market.

There are several routes of drug administration; out of which, nasal route is the most preferred over others, such as buccal, rectal, and parenteral. The buccal route is preferred by caregivers and parents for children suffering from pediatric seizures since medication can be administered even outside the hospital.

Further key findings from the study suggest:

  • Global acute repetitive seizures market size was estimated at USD 140.5 million in 2017 and is expected to register a CAGR of 47.8% over the forecast period
  • Diastat rectal gel was the dominant product segment in 2017 due to efficacy of the route of administration and affordability of the product
  • USL-261 is expected to witness a lucrative CAGR over the forecast period. USL-21 has an edge over the other drugs owing to its superior clinical profile and positive phase III results
  • North America held the largest share in 2017 due to factors, such as growing initiatives for raising awareness about epilepsy and seizures
  • Germany is anticipated to witness lucrative growth over the next decade owing to technological advancements in scientific, clinical, and medical fields

Some of the key companies in the market are: UCB S.A.; Neurelis, Inc.; and Alexza Pharmaceuticals, Inc. These companies are likely to dominate the market and gain maximum share over the forecast period

Table of Contents

Chapter 1: Methodology and Scope

  • 1.1 Research Methodology
  • 1.2 Research Scope and Assumptions
  • 1.3 List to Data Sources

Chapter 2: Executive Summary

Chapter 3: Market Variables, Trends & Scope

  • 3.1 Market Segmentation
  • 3.2 Acute Repetitive Seizures Market
  • 3.3 Market Driver Analysis
    • 3.3.1 Presence of strong pipeline and increasing initiatives for R&D
    • 3.3.2 Presence of treatment gap in adequate seizure control
    • 3.3.3 Other drivers
  • 3.4 Market restraint Analysis
    • 3.4.1 Cost of treatment
  • 3.5 Penetration Mapping
  • 3.6 Caregiver's perception on route of administration
  • 3.7 Importance of having no sedation as a side effect
  • 3.8 Opportunity Analysis

Chapter 4: Acute Repetitive Seizures: Product Outlook

  • 4.1 Acute repetitive seizures Market: Product Movement Analysis
  • 4.2 USL-261
    • 4.2.1 USL-261 market, 2013 - 2025 (USD Million)
  • 4.3 NRL-1
    • 4.3.1 NRL-1 market, 2013 - 2025 (USD Million)
  • 4.4 AZ-002
    • 4.4.1 AZ-002 market, 2013 - 2025 (USD Million)
  • 4.5 Diastat Rectal Gel
    • 4.5.1 Diastat Rectal Gel market, 2013 - 2025 (USD Million)
  • 4.6 Others
    • 4.6.1 Other acute repetitive seizures market, 2013 - 2025 (USD Million

Chapter 5: Acute repetitive seizures Market: Regional Estimates & Trend Analysis

  • 5.1 Acute repetitive seizures market share by region, 2016 & 2025
  • 5.2 North America
    • 5.2.1 North America acute repetitve seizures market, 2013 - 2025 (USD Million)
      • 5.2.1.1 U.S.
      • 5.2.1.2 U.S. acute repetitve seizures market, 2013 - 2025 (USD Million)
      • 5.2.1.2 Canada
      • 5.2.1.2 Canada acute repetitve seizures market, 2013 - 2025 (USD Million)
  • 5.3 Europe
    • 5.3.1 Europe acute repetitve seizures market, 2013 - 2025 (USD Million)
      • 5.3.1.1 Germany
      • 5.3.1.2 Germany acute repetitve seizures market, 2013 - 2025 (USD Million)
      • 5.3.1.3 U.K.
      • 5.3.1.4 U.K. acute repetitve seizures market, 2013 - 2025 (USD Million)
  • 5.4 Rest of World
    • 5.4.1 Rest of World acute repetitve seizures market, 2013 - 2025 (USD Million)

Chapter 6: Competitive Landscape

  • 6.1 Strategy Framework
  • 6.2 Company Profiles
    • 6.2.1 UCB S.A. Belgium
      • 6.2.1.1 Company overview
      • 6.2.1.2 Financial performance
      • 6.2.1.3 Product benchmarking
      • 6.2.1.4 Strategic initiatives
    • 6.2.2 Neurelis
      • 6.2.2.1 Company overview
      • 6.2.2.2 Financial performance
      • 6.2.2.3 Product benchmarking
      • 6.2.2.4 Strategic initiatives
    • 6.2.3 Valeant Pharmaceuticals North America LLC.
      • 6.2.3.1 Company overview
      • 6.2.3.2 Financial performance
      • 6.2.3.3 Product benchmarking
      • 6.2.3.4 Strategic initiatives
    • 6.2.4 Alexza Pharmaceuticals
      • 6.2.4.1 Company overview
      • 6.2.4.2 Product benchmarking
      • 6.2.4.3 Strategic initiatives
    • 6.2.5 VERITON PHARMA
      • 6.2.5.1 Company overview
      • 6.2.5.2 Financial performance
      • 6.2.5.3 Product benchmarking
      • 6.2.5.4 Strategic initiatives